ArticleCurrent medical science2024

Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.

Zhen Lu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.